Pharmacological options for acute heart failure syndromes: Current treatments and unmet needs

European Heart Journal, Supplement

Volumn 7, Issue B, 2005, Pages

  Nieminen, Markku S ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Acute disease; Congestive heart failure, classification pathophysiology therapy; Pharmacotherapy

Indexed keywords

DIGOXIN; DIURETIC AGENT; DOBUTAMINE; FUROSEMIDE; GLYCERYL TRINITRATE; INOTROPIC AGENT; ISOSORBIDE DINITRATE; LEVOSIMENDAN; MILRINONE; NESIRITIDE; VASODILATOR AGENT;

ACUTE HEART FAILURE; ACUTE HEART FAILURE SYNDROME; BLOOD PRESSURE; CLINICAL PRACTICE; EVIDENCE BASED MEDICINE; HEADACHE; HEART ARRHYTHMIA; HEART INDEX; HEART OUTPUT; HEART RATE; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE TACHYCARDIA; HEMODYNAMICS; HUMAN; HYPOTENSION; LUNG CAPILLARY PRESSURE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIDE EFFECT; TACHYPHYLAXIS;

EID: 17144412993     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/sui009     Document Type: Review

References (32)

1. McAlpine HM, Cobbe SM. Neuroendocrine changes in acute myocardial infarction. Am J Med 1988;84:61-66.
2. 2+ management in cardiac myocytes. Ann N Y Acad Sci 2004;1015:28-38.
3. Cleland JG, Swedberg K, Poole-Wilson PA. Successes and failures of current treatment of heart failure. Lancet 1998;352(Suppl. 1): SI19-SI28.
4. Sharma M, Teerlink JR. A rational approach for the treatment of acute heart failure: current strategies and future options. Curr Opin Cardiol 2004;19:254-263.
5. Neuberg GW, Miller AB, O'Connor CM et al. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J 2002;144:31-38.
6. Francis GS, Siegel RM, Goldsmith SR et al. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med 1985;103:1-6.
7. Northridge D. Frusemide or nitrates for acute heart failure? Lancet 1996;347:667-668.
8. Mehta RL, Pascual MT, Soroko S et al. Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA 2002;288:2547-2553.
9. Chatterjee K, Parmley WW, Massie B et al. Oral hydralazine therapy for chronic refractory heart failure. Circulation 1976;54:879-883.
10. Larsen AI, Goransson L, Aarsland T et al. Comparison of the degree of hemodynamic tolerance during intravenous infusion of nitroglycerin versus nicorandil in patients with congestive heart failure. Am Heart J 1997;134:435-441.
11. Cotter G, Metzkor E, Kaluski E et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet 1998;351:389-393.
12. Guiha NH, Conn JN, Mikulic E et al. Treatment of refractory heart failure with infusion of nitroprusside. N Engl J Med 1974;291:587-592.
13. Johnson W, Omland T, Hall C et al. Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J Am Coll Cardiol 2002;39:1623-1629.
14. Mukoyama M, Nakao K, Hosoda K et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991;87:1402-1412.
15. Zellner C, Protter AA, Ko E et al. Coronary vasodilator effects of BNP: mechanisms of action in coronary conductance and resistance arteries. Am J Physiol 1999;276:H1049-H1057.
16. Protter AA, Wallace AM, Ferraris VA et al. Relaxant effect of human brain natriuretic peptide on human artery and vein tissue. Am J Hypertens 1996;9:432-436.
17. Fonarow GC. The treatment targets in acute decompensated heart failure. Rev Cardiovasc Med 2001;2(Suppl. 2):S7-S12.
18. Mills RM, LeJemtel TH, Horton DP et al. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. J Am Coll Cardiol 1999;34:155-162.
19. Colucci WS, Elkayam U, Horton DP et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000;343:246-253.
20. Burger AJ, Elkayam U, Neibaur MT et al. Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy. Am J Cardiol 2001;88:35-39.
21. Burger AJ, Horton DP, LeJemtel T et al. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am Heart J 2002;144:1102-1108.
22. Abraham WT, Lowes BD, Ferguson DA et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail 1998;4:37-44.
23. Silver MA, Horton DP, Ghali JK et al. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol 2002;39:798-803.
24. Siostrzonek P, Koreny M, Delle-Karth G et al. Milrinone therapy in catecholamine-dependent critically ill patients with heart failure. Acta Anaesthesiol Scand 2000;44:403-409.
25. Heino A, Hartikainen J, Merasto ME et al. Effects of dobutamine on splanchnic tissue perfusion during partial superior mesenteric artery occlusion. Crit Care Med 2000;28:3484-3490.
26. Capomolla S, Pozzoli M, Opasich C et al. Dobutamine and nitroprusside infusion in patients with severe congestive heart failure: hemodynamic improvement by discordant effects on mitral regurgitation, left atrial function, and ventricular function. Am Heart J 1997;134:1089-1098.
27. Haikala H, Linden IB. Mechanisms of action of calcium-sensitizing drugs. J Cardiovasc Pharmacol 1995;26(Suppl. 1):S10-S19.
28. Pataricza J, Hohn J, Petri A et al. Comparison of the vasorelaxing effect of cromakalim and the new inodilator, levosimendan, in human isolated portal vein. J Pharm Pharmacol 2000;52:213-217.
29. Follath F, Cleland JG, Just H et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002;360:196-202.
30. Slawsky MT, Colucci WS, Gottlieb SS et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation 2000;102:2222-2227.
31. Haikala H, Pollesello P. Calcium sensitivity enhancers. IDrugs 2000;3:1199-1205.
32. Cleland JG, Ghosh J, Freemantle N et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology. WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail 2004;6:501-508.